By Colin Kellaher
Nymox Pharmaceutical Corp. on Thursday said it has filed for Food and Drug Administration approval of fexapotide triflutate for the treatment of men with benign prostatic hyperplasia.
The biopharmaceutical company said it also plans to submit applications in other major markets in the near term.
Nymox has previously said the last major drug innovations for benign prostatic hyperplasia, an age-related disorder also known as prostate gland enlargement, were first introduced more than 30 years ago.
Write to Colin Kellaher at Click Here To Get Funded!